Viridian Therapeutics, Inc.\DE - 8-K Filing

Viridian Therapeutics reports Q3 2026 net product revenue of $24.7 million from Lumvoa and maintains $955.2 million in cash liquidity. (Items: 2.02 Results of Operations and Financial Condition On November 4, 2026, Viridian Therapeutics, Inc, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 4, 2026, 12:11 UTC

Tickers: $VRDN

Read the full article at SEC EDGAR

Part of the story DARLING INGREDIENTS INC. - 8-K Filing (11 articles)

More Regulatory news

Cohen & Co Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:48 UTC
UNITED BANCORP INC /OH/ - 10-Q Filing SEC EDGAR · November 12, 2026, 15:33 UTC
PATRIOT GOLD CORP - 10-Q Filing SEC EDGAR · November 12, 2026, 15:32 UTC
First Digital Acquisition Corp Ltd. - 8-K Filing SEC EDGAR · November 12, 2026, 15:29 UTC
GROOVE BOTANICALS INC. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:24 UTC
Johnson Controls International plc - 10-K Filing SEC EDGAR · November 12, 2026, 15:24 UTC
OLD NATIONAL BANCORP /IN/ - 8-K Filing SEC EDGAR · November 12, 2026, 15:20 UTC
AMTECH SYSTEMS INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:16 UTC
REGIONAL HEALTH PROPERTIES, INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:09 UTC
Bitwise Avalanche ETF - 8-K Filing SEC EDGAR · November 12, 2026, 15:06 UTC